Table 6.

Research agenda in CAPA

Epidemiology	Determine the true epidemiology of CAPA Frequency of IATB in CAPA Identification of host/risk factors
Diagnosis	Markers that discriminate between Aspergillus respiratory tract colonization and tissue invasion Validation of Aspergillus biomarkers in NBL and BA/TA Determine the immune status of the host (e.g. FACS)
Strategy	Role for antifungal prophylaxis Management of COVID-19 patients with positive upper respiratory tract culture
Antifungal agents	Benefit of nebulized antifungals in IATB Role of liposomal amphotericin B in the ICU-setting Effect of sequestration and drug interactions of antifungals on exposure (i.e. ECMO; CRRT)
Therapy	Implications of antiviral and host-directed therapy for CAPA risk and outcome Host directed therapy: dampening or boosting immune response or both, dependent on host immune status